Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 1/2 4Phase 3 2Phase 1 2Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Breast Neoplasms 1

Interventions

Paclitaxel 9Magnetic Resonance Spectroscopy 8Cyclophosphamide 8Cisplatin 8Carboplatin 8Granulocyte Colony-Stimulating Factor 7Etoposide 7Radiotherapy, Intensity-Modulated 6Nivolumab 6Leucovorin 6Filgrastim 6Drug Therapy 6Doxorubicin 6Radiotherapy 5Oxaliplatin 5Fluorouracil 5Docetaxel 5Bevacizumab 5pembrolizumab 4gallium 68 PSMA-11 4Taxes 4Sirolimus 4Rituximab 4Pemetrexed 4Melphalan 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Dexamethasone 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Has results × NVP-BKM120 × Clear all
NCT01572727 2017-03-09

BELLE-4

Novartis

Phase 2/3 Completed
416 enrolled 11 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡